abbv-383
abbvie
dr. peter voorhees presented impressive results from phase 1, the first in-human study using monotherapy abbv-383 in rrmm pts. with endpoint findings that show deep and durable responses w/ manageable crs. orr of 60% was observed at 60mg in esc + exp cohorts. #ims2022 
To cure myeloma by fostering research, education and excellence in clinical care worldwide.